Trial · NCT05556616
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 3 | |
| Overall Study | STARTED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 4 | |
| Overall Study | STARTED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 4 | |
| Overall Study | STARTED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 3 | |
| Overall Study | STARTED | Group 2 (RRMM Doublets) Arm 4: Modakafusp Alfa + Bortezomib | 0 | |
| Overall Study | STARTED | Group 3 (RRMM Triplets): Modakafusp Alfa + Pomalidomide + Bortezomib | 0 | |
| Overall Study | STARTED | Group 3 (RRMM Triplets): Modakafusp Alfa + Daratumumab + Pomalidomide | 0 | |
| Overall Study | COMPLETED | Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 2 | |
| Overall Study | COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 1 | |
| Overall Study | COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 2 | |
| Overall Study | COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 2 | |
| Overall Study | COMPLETED | Group 2 (RRMM Doublets) Arm 4: Modakafusp Alfa + Bortezomib | 0 | |
| Overall Study | COMPLETED | Group 3 (RRMM Triplets): Modakafusp Alfa + Pomalidomide + Bortezomib | 0 | |
| Overall Study | COMPLETED | Group 3 (RRMM Triplets): Modakafusp Alfa + Daratumumab + Pomalidomide | 0 | |
| Overall Study | NOT COMPLETED | Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 1 | |
| Overall Study | NOT COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg | 3 | |
| Overall Study | NOT COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg | 2 | |
| Overall Study | NOT COMPLETED | Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2 | 1 | |
| Overall Study | NOT COMPLETED | Group 2 (RRMM Doublets) Arm 4: Modakafusp Alfa + Bortezomib | 0 | |
| Overall Study | NOT COMPLETED | Group 3 (RRMM Triplets): Modakafusp Alfa + Pomalidomide + Bortezomib | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05556616/flow